• SPX
  • $5,712.69
  • -0.28 %
  • -$16.11
  • DJI
  • $41,853.54
  • 0.14 %
  • $58.93
  • N225
  • $38,474.90
  • 1.11 %
  • $421.23
  • FTSE
  • $8,163.34
  • -0.26 %
  • -$20.90
  • IXIC
  • $18,290.08
  • 0.61 %
  • $110.09
PDS Biotechnology Corporation (PDSB) Stock Price, News & Analysis

PDS Biotechnology Corporation (PDSB) Stock Price, News & Analysis

Currency in USD Disclaimer

$3.23

-$0

(0%)

Day's range
$3.16
Day's range
$3.23
50-day range
$2.83
Day's range
$4.29
  • Country: US
  • ISIN: US70465T1079
52 wk range
$2.53
Day's range
$6.85
  • CEO: Dr. Frank K. Bedu-Addo Ph.D.
  • Website: Visit Site


We are preparing, please wait

Analyst Ratings

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

Stock Score/grades

The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company

  • Altman Z Score -2.65
  • Piotroski Score 2.00
  • Grade Buy
  • Symbol (PDSB)
  • Company PDS Biotechnology Corporation
  • Price $3.23
  • Changes Percentage (0%)
  • Change -$0
  • Day Low $3.16
  • Day High $3.23
  • Year High $6.85

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, focuses on developing multifunctional cancer immunotherapies. Its lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, human papillomavirus associated malignancies, and cervical cancer. The company is also developing various product candidates, which are in preclinical trials, including PDS0102 T-cell receptor gamma alternate reading frame protein (TARP) for treating prostate and breast cancers; PDS0103 (MUC-1) for ovarian, colorectal, lung, and breast cancers; and PDS0104, which include Tyrosinase-related protein 2 for the treatment of melanoma. In addition, it is developing PDS0201 for treating tuberculosis; PDS0202, an influenza vaccine candidate; and PDS0203, a vaccine for the prevention of COVID-19. The company has a license and collaboration agreements with National Institutes of Health, Merck Eprova AG, The U.S. Department of Health and Human Services, and MSD International GmbH. PDS Biotechnology Corporation was founded in 2005 and is based in Florham Park, New Jersey.

  • Last Earnings
  • Ex-Dividend for 5/16 Dividend
  • Dividend Payable
  • Today N/A
  • Next Earnings (Estimated) 11/11/2024
  • Fiscal Year End N/A

  • Average Stock Price Target $9.00
  • High Stock Price Target $9.00
  • Low Stock Price Target $9.00
  • Potential Upside/Downside N/A
  • Consensus Rating Strong Sell
  • Rating Score (0-4) N/A
  • Research Coverage N/A

  • EPS (Most Recent Fiscal Year) -$1.37
  • Trailing P/E Ratio -2.13
  • Forward P/E Ratio -2.13
  • P/E Growth -2.13
  • Net Income $-42,942,198

Income Statement

Quarterly

Annual

Enter your phone number to get Breaking News Updates

Stay ahead with instant updates! Enter your phone number for breaking news alerts, ensuring you're always in the know with the latest developments.


We are preparing, please wait

Portfolio Sync Solutions

Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced

GET STARTED
Portfolio Sync Solutions
×
New Alert

Select an alert type

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.

New Alert

Setup alert

×

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.

×

Log In


or

download app using google store Continue with Google download app using apple Continue with Apple

Email Verification

An email with a verification code has been sent to your email address.

Welcome to Stocks.News!

Create Your Account

Email Verification

An email with a verification code has been sent to your email address.